Alliance Global Partners lowered the firm’s price target on Aquestive Therapeutics to $5.50 from $7 and keeps a Buy rating on the shares, citing revised share count estimates and a slightly delayed Anaphylm launch compared to the firm’s previous estimates.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AQST:
- Aquestive Therapeutics Presents to Investors and Analysts
- Aquestive Therapeutics sees FY24 revenue $48M-$51M, consensus $50.21M
- Aquestive Therapeutics reports Q1 EPS (17c), consensus (8c)
- Aquestive Therapeutics Shares Investor Presentation Update
- Aquestive Therapeutics options imply 12.3% move in share price post-earnings